Mobile

Open label, phase II study to evaluate efficacy and safety of oral nilotinib in Philadelphia positive (Ph+) chronic myelogenous leukemia (CML) pediatric patients

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000200-41

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. To assess efficacy of nilotinib in pediatric patients with Ph+ CML-CP resistant or intolerant to either imatinib or dasatinib 2. To assess efficacy of nilotinib in pediatric patients with Ph+ CML-AP resistant or intolerant to either imatinib or dasatinib 3. To assess efficacy of nilotinib in pediatric patients with newly diagnosed Ph+ CML-CP

Critère d'inclusion

  • - leukemia - leukemia,pediatric - leukemia, myleiod - leukemia, mylegenous, chronic - leukemia, mylegenous, accelerated - BCR-ABL positive - myeloproliferative disorder - bone marrow disease - hematologic diseases - neoplastic processes

Liens